...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Great Presetation today

BDAZ/fouremm - My understanding is the same as fouremm's. When the spin-off happened there were 75 million shares of Zenith Epigenetics Inc which is now Zenith Capital Corp that currently has 125 mil shs outstanding (132 mil fully diluted) and Zenith Epigenetics Ltd is the operating company with all the IP. If the funds raised are through Zenith Capital Corp then I believe that would represent the third dilutive event to the royalties which as fouremm stated is exactly opposite from what we have been told on a number of occasions.

This is IMO

tada

Share
New Message
Please login to post a reply